System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Julien Dumurgier is an expert in Neurology at Hôpital Lariboisière (France). As of October 2026, ScienceLeadR ranks Julien Dumurgier in the top 1% of experts worldwide for Alzheimer Disease, Dementia and Neurocognitive Disorders. Julien Dumurgier has authored 215 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 651 (community average: 125). How the SLR is computed.

LeadR Profile

Julien Dumurgier Hôpital Lariboisière France
651 ScienceLeadR Reputation 651

Unlock

Register Login
Network Map

Neurology

Subspecialties: Psychiatry - Public Health - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 215

Citations

Citations: 7 692 1st author: 26 Last author: 17 Unique author: 0

Main journals

Alzheimers Dement 24
Alzheimers Res Ther 22
J Alzheimers Dis 15
Rev Neurol (Paris) 13
Neurology 10

Best Journals

BMJ 2
JAMA 1
Lancet Public Health 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinic.
PMID 42360686 — cross-sectional studies, alzheimer disease, adiponectin, biomarkers, sex, amyloid, memory, plasma		Metab Brain Dis20260
Methodological approaches to account for assay changes in longitudinal biomarker analysis: insights from Alzheimer's blood biomarkers in the MEMENTO cohort.
PMID 42265779 — research design, blood, alzheimer disease, biomarkers		Alzheimers Res Ther20260
Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.
PMID 42265349 — genes, alzheimer disease, brain, amyloid, cognition		Commun Med (Lond)20260
Clinical correlates of sleep profiles in dementia with Lewy bodies: a latent class approach.
PMID 42129862 — dementia, lewy bodies, alzheimer disease, sleep, cognitive dysfunction, signs and symptoms, cognition disorders, sleep initiation and maintenance disorders		Alzheimers Res Ther20260
Eligibility for lecanemab treatment in a French memory clinic setting.
PMID 41872339 — research design, neurosurgery, biomarkers, therapeutics, memory, neurology		J Neurol20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 2
Phase 3 1
Phase 4 1

By status:

Completed 2
Recruiting 1
Unknown 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Donepezil Versus Non drug Treatment in Alzheimer s Disease
NCT04661280 — choline, donepezil, alzheimer disease, pharmaceutical preparations, therapeutics		Phase 3Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS